NCI SBIR Investor Forum –18 Leading NCI SBIR-Funded Oncology Companies Announced

April 5, 2012

March 20, 2012 - NCI SBIR has just announced the 18 NCI SBIR-funded companies with leading innovations in cancer therapeutics, diagnostics, and devices selected to present at this year’s Forum.  The companies selected to present at this year’s meeting include:

Therapeutics

  • A&G Pharmaceutical – Developing an oncology theranostic product pipeline around its proprietary biomarker GP88, particularly for use in breast and lung cancers.
  • AcuityBio – Developing a unique biocompatible, biodegradable drug delivery platform technology to prevent post-surgical tumor recurrence in early-stage lung cancer patients.
  • Altor BioScience Corporation –Commercializing novel immunotherapeutics based on three novel technology platforms. Altor’s lead molecule is based on its revolutionary STAR™ technology and is currently in two Phase II trials for cancer indications.
  • Celek Pharmaceuticals – Developing the first targeted drug for non-muscle invasive bladder cancer.
  • Centrose – Developing a novel antibody-drug conjugation (ADC) technology that targets a wide variety of diseased cells, to work together with its first-ever synergistic drug targeting system, called the Extracellular Drug Conjugate System (EDC). The specificity of EDCs to diseased cells may increase safety and efficacy.
  • NovoMedix – Developing first-in-class small molecule inhibitors of translation initiation as targeted therapies, with an initial focus on breast cancer.
  • Omniox – Developing a new biotherapeutics platform to eliminate tumor hypoxia. Lead candidates substantially reduce tumor hypoxia and enhance the effects of radiation in models of human brain cancer.
  • Thermedical – Developing SERF™ Ablation to rapidly and completely ablate large solid tumors, holding the promise of a more effective therapy for liver cancer patients.

Diagnostics, Imaging Technologies, and Research Tools

  • ApoCell – Commercializing ApoStream™, an antibody independent technology for the capture of rare, viable circulating tumor cells from blood.
  •  Arbor Vita Corporation – Using technology that stems from its proprietary PDZ proteomics platform, allowing for the development of novel paired diagnostics and therapeutics.
  • BioMarker Strategies – Developing the SnapPath™ biomarker testing system, an automated live tumor cell processing platform that enables next-generation biomarker tests to help guide targeted drug therapy selection.
  •  Firefly BioWorks – Introducing a universal biomarker detection platform that scales from exploratory discovery to bedside diagnostics, starting with multiplexed microRNA detection to diagnose cancer and other diseases.
  • Gamma Medica – Developing state-of-the-art, solid-state digital gamma photon detection technology that is applied to both clinical and preclinical medical imaging. The FDA-approved LumaGEM® molecular breast imaging scanner detects cancer where mammography often misses it.
  •  Guided Therapeutics – Developing a rapid and painless testing platform for the early detection of disease at the cellular level. The company’s first planned product is a non-invasive device used to detect cervical cancer instantly and at the point of care.
  • Metabolomx – Developing a breath test for lung cancer, based on the metabolomic fingerprint present in exhaled breath.
  •  Nortis – Developing ”body-on-a-chip” in vitro assays that utilize tissues and organs grown from human-derived cells in disposable, chip-like devices to improve drug development and testing.
  • Oncoscope – Developing diagnostic medical devices that use proprietary optical technologies for non-invasive real-time in vivo identification of pre-cancerous epithelial tissue.
  • Vala Sciences – Applying cutting edge high-content microscope technology, custom image analysis software, and multiplex biomarker imaging to enable quantitative medical diagnostics.

The Investor Forum provides a chance to learn more about upcoming initiatives from NCI. With $115 million in funding annually, NCI SBIR is one of the largest sources of early stage funding for small businesses in the cancer space. We prospect for companies on the leading edge of innovation and provide them with the funding necessary to advance their technologies through development and towards commercialization. 

 

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.